Mimetics Causing Cancers to its Users?

Despite the decision of a Los Angeles Superior Court Judge to overturn a $6.5 million dollar verdict, Actos Lawsuits continue to move forward.

In April of this year, a jury awarded $6.5 million to a man who alleged that Actos caused him develop bladder cancer. However, Takeda Pharmaceuticals, the manufacturer of the popular Type 2 Diabetes medication, filed a motion claiming that the company was not responsible for the plaintiff’s condition. The judge granted Takeda’s motion claiming that the Plaintiff’s Actos Lawyers did not provide sufficient evidence to support the plaintiff’s claim that Actos caused his Bladder Cancer.

While Actos Lawyers may have lost a battle, they have not yet lost the war.  Patients who developed Bladder Cancer after prolonged use of Actos continue to file Actos Bladder Cancer Lawsuits against Takeda Pharmaceuticals. As of August 15th, there are more than 2,500 Actos Bladder Cancer Lawsuits pending in the federal Actos Multi-District Litigation (MDL).

Actos was approved by the Food and Drug Administration (FDA) for treatment of type 2 Diabetes in 1998. In June 2011, the FDA warned that using Actos for one year or more could increase a patient’s risk of developing bladder cancer. Following the warning, Actos was recalled in Germany and France. India recalled Actos two years later. To this date, an Actos recall has been issued in the United States.

Earlier this year, the Food and Drug Administration (FDA) issued an alert on the Byetta and Januvia following the publication of medical journals suggesting a link between Byetta and pancreatic cancer and Januvia and pancreatic cancer.

Both of these drugs are a member of the same class of diabetes drugs known as incretin mimetics because they mimic hormones the body produced to stimulate the release of insulin.

The warning was prompted after a medical study demonstrated that individuals taking incretin mimetics such as Byetta and Januvia had an increased risk of developing pancreatic cancer or pancreatitis.

However, the European Medical Agency (EMA) recently published a report suggesting that the study linking Byetta and Januvia with pancreatic cancer was flawed and that the data did not support the idea that Byetta and Januvia could directly lead to the development of pancreatic cancer. There was however, a small incidence of pancreatitis in clinical trials.

Based upon the findings of the EMA, the FDA advised that it will not issue a label change for Byetta and Januvia at this time.

While the EMA and FDA may not see enough evidence to link Byetta and Januvia with pancreatic cancer, the growing number of plaintiffs involved in the Byetta lawsuits and Januvia lawsuits may disagree.

Diabetic patients who took Byetta and Januvia and developed pancreatic cancer are seeking out Januvia and Byetta Lawyers to file Byetta Cancer Lawsuits and Januvia Cancer Lawsuits on their behalf against the manufacturers. While these patients may be living contradictions of the EMA’s latest report, those findings may end up hurting their Byetta and Januvia Cancer Lawsuits.

If you are taking Byetta, Januvia or other incretin mimentics and are concerned about the risk of developing pancreatic cancer or pancreatitis, you should speak with your doctor. Do not discontinue the use of these drugs on your own. While Byetta and Januvia may increase the risk of pancreatic cancer for some individuals, other patients may benefit greatly from these drugs. We’ve had followers on our facebook page tell us that Januvia has worked wonders for them. When it comes to any medical condition, including Diabetes and Pancreatic cancer, everyone’s body reacts differently.

So, What is your experience with Byetta and Januvia? Are you concerned about pancreatic cancer?

You Might Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>